Aurobindo Pharma Q4 Result Preview: PAT Likely To Decline 11% Yoy; US Sales May Grow Up To 18%
Aurobindo Pharma Q4 result preview: Revenue may see a growth of 9 per cent to Rs 6,316 crore against Rs 5,809 crore logged in the year-ago period.
Written By: Zee Business Video Team